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Aims: Lipoprotein (a) [Lp(a)] levels have shown wide ethnic variations. Sparse data on mean
Lp(a) levels, its link with clinical variables and severity of coronary artery disease (CAD) in
North Indian population needed further studies.
Methods: 150 patients, each of single vessel disease (SVD), double vessel disease (DVD) and
triple vessel disease (TVD) with 150 healthy controls were drawn for the study. Serum Lp(a)
estimation was performed by immunoturbidimetric method.
Results: Lp(a) had a skewed distribution. Median Lp(a) level was significantly raised in cases as
compared to controls (median 30.30 vs. 20 mg/dl, p < 0.001). Cases with acute coronary syn-
drome (ACS, 55.8%) had significantly higher median Lp(a) levels as compared to those with
chronic stable angina (35.4mg/dl vs. 23mg/dl, p< 0.001). Significant difference inmedian Lp(a)
levels were observed in patients with DVD or TVD versus control (30, 39.05 vs 20 mg/dl,
p < 0.008). Lp(a) level was found to be an independent risk factor for CAD (AOR{adjusted odds
ratio} 1.018, 95% CI 1.010e1.027; p< 0.001). Analysis using Lp(a) as categorical variable showed
that progressive increase in Lp(a) concentration was associated with increased risk of CAD
[AOR from lowest to highest quartile (1, 1.04, 1.43 and 2.65, p value for trend ¼ 0.00026)].
Multivariably AOR of CAD for subjects with Lp(a) in the highest quartile (above 40 mg/dl)
compared to those with Lp(a) 40 mg/dl was 2.308 (95% CI 1.465e3.636, p < 0.001).
Conclusion: Lp(a) above 40 mg/dl (corresponding to 75th percentile)assessed by an isoform
insensitive assay is an independent risk factor for CAD. Raised Lp(a) level is also associated
with increased risk of ACS and multivessel CAD.
Copyright ª 2014, Cardiological Society of India. All rights reserved.risk factors have failed to explain the increasing burden of
1. Introduction
Coronary artery disease (CAD) has become one of the major
killers in developing countries including India. ConventionalDayanand Vihar, New D
hoo.in, drabhishekgoyal1
ciety of India. All rightsCAD, thus necessitating the need to search for newer risk
factors like insulin resistance, thrombogenic factors, infec-
tion, inflammation and lipoprotein(a) [Lp(a)]. Lp(a) excess in-
crease the risk of premature CAD 3e100 fold depending on theelhi 92, India. Tel.: þ91 9501102345.
1@gmail.com (A. Goyal).
reserved.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 2 7 2e2 7 9 273absence or presence of concomitant risk factors.1e4 Uninflu-
enced by age, sex, diet or environmental factors, Lp(a) values
are genetically determined by Lp(a) gene located on chromo-
some 6q26-27 and stable lifelong levels are attained by age of
two.4,5 Though earlier studies on relationship between Lp(a)
and CAD had shown negative results,6,7 recently multiple
studies have shown that elevated Lp(a) is independently and
linearly predictive of future adverse coronary events.8,9 Lp(a)
levels have shown worldwide ethnic variation with different
levels associated with CAD in different populations. Data on
levels of Lp(a) associated with risk of CAD from large North
Indian population is still lacking, though there are few small
studies to suggest its association with CAD.1,2,10e13 Thus this
study was carried out to find out the level of Lp(a) indepen-
dently associated with risk of CAD in the North Indian popu-
lation (defined as Hindi speaking population residing from
birth in the states of Delhi, Punjab, Haryana, Uttar Pradesh,
Uttaranchal or Himachal Pradesh) and also its association
with various clinical variables and conventional risk factors of
CAD.2. Materials & methods
This study is a prospective cross sectional case control study
and was approved by the institutional ethical committee.
Successive patients of CAD with unstable angina having TIMI
risk score of 3 or higher14 and of chronic stable angina who
were referred for coronary angiography were enrolled be-
tween January 2010 and June 2012. Selective coronary angi-
ography was carried out using Judkin’s technique in all
patients. The right coronary artery was considered to be a
single artery and the left coronary artery was subdivided into
left anterior descending, circumflex and obtuse marginal
branches. Observations of diagonals and other small vessel
branches were not tabulated. Patients with left main disease
were considered to be having double vessel disease. The ar-
teries were judged by visual estimation to be normal, 50%,
75%, 90% and 100% obstructed, according to the maximum
obstruction in any projection. According to the results of
angiography, the patients were divided into three subgroups;
single, double and triple vessel disease (disease defined by
obstruction 50%). 150 patients each of single vessel disease
(SVD), double vessel disease (DVD) and triple vessel disease
(TVD) formed our study group of patients.
150 healthy, controls were selected from the attendants
who were not first degree relatives of the patients. Presence of
CAD in controls was ruled out by detailed clinical history,
ECG, echocardiography and stress tests like treadmill test or
dobutamine stress echocardiography if required. An
informed consent was taken from all the subjects. Patients
with history of recent ST elevation myocardial infarction (<6
weeks), chronic liver and kidney disease, thyroid disorders,
stroke, Familial hypercholesterolemia, acute/chronic in-
fections and on therapy with sex hormones or anabolic ste-
roids were excluded from the study. Fasting blood samples
were drawn from all the participants of the study (cases and
controls) 5 ml of venous blood was withdrawn and serumwas
immediately separated by centrifugation. The serum was
stored at 70 C for subsequent analysis. Total cholesterol,triglycerides and high-density lipoprotein cholesterol were
estimated using commercial kits on Beckman CX4 auto-
analyzer. Low-density lipoprotein (LDL) cholesterol was
calculated using Friedewald’s formula.15 Serum Lp(a) esti-
mation was performed using quantitative Latex- enhanced
Immunoturbidimetric test using human Lp(a) kit (Human
Gesselschaft, Weisbaden, Germany). Strict external quality
control using sera with known values was performed to
validate the results.3. Statistical analysis
Data has been expressed as mean  SE for quantitative vari-
ables and as frequency (%) for qualitative variables. If quan-
titative variables followed normal distribution, unpaired
students‘t’ test was used for comparing the data between two
groups. In case of non-normal distribution, Mann Whitney U
test was used to compare distribution between two groups
and formore than two groups, KruskalWallis test was used. In
case of multiple comparisons among the groups, the Bonfer-
roni correction was applied. Statistical significance of cate-
gorical variables was determined by Chi-square test and
Fisher’s Exact test. Chi-square for trend was applied for un-
adjusted odds ratio and Likelihood ratio test (LRT) was used
for testing trend for adjusted odds ratio (AOR) of Lp(a),when
divided into quartiles. p < 0.05 was taken as a level of statis-
tical significance. Univariate regression analysis was carried
out using CAD as the dependant variable and age, sex, dia-
betes, hypertension, smoking, triglycerides, HDL cholesterol,
LDL cholesterol, and Lp(a) as independent variables. Variables
which showed an association with CAD (p  0.25) in the uni-
variate analysis were included as independent variables for
multivariable logistic regression analysis. Statistical analysis
was done using Microsoft excel and windows based SPSS
version 16.0(Chicago, IL). As one of the aim of a study was to
assess the relationship of Lp(a) with severity of CAD, based on
the study by Gupta et al11 sample size calculated was a min-
imum of 95 subjects each of SVD, DVD, TVD and controls to
have a power of 90%with 5% level of significance taking effect
size 0.20 with pooled standard deviation of Lp(a) of 26. As Lp(a)
has a skewed distribution further 10% was added to each
group. Hence a minimum of 105 subjects were required in
each group. As till date there has been no adequately powered
trial to define the Lp(a) level associated with risk of CAD, we
wanted to apply multivariable logistic regression to find the
independent effect of Lp(a) on CAD .In our model, there were
14 independent risk factors including 3 dummy variables of
Lp(a). As application of multivariable logistic regression re-
quires a minimum of 10 subjects per variable (cases or control
whichever is less) we decided to recruit 150 healthy subjects
as controls and accordingly 150 patients each of SVD, DVD and
TVD were enrolled.4. Results
Descriptive statistics on study population is presented in
Table 1. There was no significant difference in age [mean (SE)
53.4 0.478 versus 52.34 0.883, p¼ 0.15] or sex ratio between
Table 1 e Baseline clinical characteristics and lipid profile
of patients and controls.
Parameters Cases
(n ¼ 450)
Controls
(n ¼ 150)
p
value
Agea (years) 53.74  0.478 52.34  0.883 0.15
Sex (male/female) 363/87 127/23 0.273
BMIa (kg/m2) 24.82  0.191 24.47  0.332 0.36
Diabetes mellitus n (%) 145 (32.2) 17 (11.3) <0.001
Hypertension n (%) 209 (46.4) 61 (40) 0.218
Smoking n (%) 198 (44) 58 (38.6) 0.253
Family history of
CAD n (%)
112 (25) 28 (18.7) 0.145
Chronic stable
Angina n (%)
199 (44.2) e
Unstable Angina n (%) 251 (55.8) e
Total cholesterol (mg/dl)
Mean  S.E 138.5  3.537 142.91  4.599
Median (IQR) 127
(108.7e152)
134 (115e155) 0.008
LDL cholesterol (mg/dl)
Mean  S.E 82.12  3.454 73.59  3.858
Median (IQR) 68.2
(54.75e93.40)
65.3
(56e80.20)
0.84
Triglycerides (mg/dl)
Mean  S.E 151.1  3.455 137.59  4.476
Median (IQR) 134.5
(100e179.25)
131.5
(92e162.75)
0.12
HDL cholesterol (mg/dl)
Mean  S.E 30.01  0.361 32.69  0.674
Median (IQR) 30 (25e35) 32 (27e36.25) 0.001
Lp(a) (mg/dl)
Mean  S.E 41.11  1.756 27.20  1.705 <0.001
Median (IQR) 30.3 (14e55.92) 20 (12e40) <0.001
BMI e Body Mass Index, CAD e Coronary Artery Disease, S. E e
Standard Error, IQR e Interquartile Range.
a Values are in mean  S.E.
Table 2 e Lp(a) levels (mg/dl) in patients with CAD
according to clinical presentation, angiographic severity
and LDL levels.
Variable Mean  S.E
(mg/dl)
Median
(mg/dl)
IQR
(mg/dl)a
Unstable Angina (n ¼ 251) 45.5  2.493 35.41 19e57.30
Stable Angina (n ¼ 199) 35.5  2.638 23.0 13e53
Single vessel disease
(n ¼ 150)
32.90  2.265 23.00 11e50.25
Double vessel disease
(n ¼ 150)
40.22  2.861 30.002 15e55.55
Triple vessel disease
(n ¼ 150)
50.20  3.68 39.052,3 16.5e66.2
LDLeC (<130 mg/dl)
(n ¼ 417)
39.69  1.754 304 14e54
LDLeC (>130 mg/dl)
(n ¼ 33)
59.03  8.593 52.71 18.5e81.55
1p < 0.001 Unstable Angina versus stable Angina.
2p < 0.008 versus control [according to Bonferroni correction for
multiple comparisons, p value less than (0.05/6) 0.008 is considered
significant].
3p < 0.008 versus single vessel disease.
4Significant (p ¼ 0.02).
a Interquartile range.
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difference between cases and controls with respect to con-
ventional risk factors for CAD except that diabetes mellitus
was present in higher number of cases compared to controls
(32.2% versus 11.3% p < 0.001 Table 1). 55.8% of our patients
had unstable angina at the time of presentation and rest had
chronic stable angina. As majority of our patients were
established cases of CAD, most of them were on standard
doses of lipid lowering drugs [statins (n ¼ 403,89.5%), fibrates
(fenofibrate, n ¼ 84,18.6%), ezetimibe (n ¼ 76, 16.8%)] but none
were on niacin.
In our study population the various lipid components (total
cholesterol, LDL cholesterol, HDL cholesterol triglycerides)
and Lp (a) had a skewed distribution. So median along with
interquartile range has been provided along with mean (SE).
There was no significant difference in LDL cholesterol or tri-
glyceride between cases or controls but HDL cholesterol was
significantly lower in cases compared to controls (Table 1).
The median Lp(a) level was significantly higher in cases
compared to controls (30.3 mg/dl versus 20 mg/dl p < 0.001).
Themedian Lp(a) levels showed a trend towards higher values
with increasing severity of disease (Table 2) and Bonferroni
pair comparison test showed a significant difference in Lp(a)
levels between controls and patients with DVD or TVD and
between patients with SVD and TVD (Table 2). The Lp(a) levelwas also significantly higher in patients with unstable angina
compared to stable angina (Table 2). Age, sex, diabetes melli-
tus, hypertension, smoking, total cholesterol and triglyceride
showed no significant influence on Lp(a) level (data not
shown). However Lp(a) was significantly higher in cases with
LDL cholesterol >130 mg/dl compared to those with LDL
cholesterol <130 mg/dl (Table 2). Table 3 shows the results of
regression analysis (univariable and multivariable) using CAD
as a dependent variable. Univariate anlalysis showed diabetes
mellitus (p < 0.001) HDL cholesterol (p < 0.001) triglyceride
(p ¼ 0.04) and Lp(a) (p < 0.001) were associated with CAD. In
multivariable regression analysis, we included only risk fac-
tors which had a p value <0.25 in univariate analysis i.e. age
(p ¼ 0.15) hypertension (p ¼ 0.218) LDL (p ¼ 0.197) and also
smoking (p ¼ 0.253) as it was very close to cut off value of
<0.25. Table 3 shows the results of multivariable regression
analysis in which diabetes mellitus (p ¼ 0.001) smoking
(p ¼ 0.015) HDL (p < 0.001) and Lp(a) (p < 0.001) showed an
independent association with CAD. In this model, where Lp(a)
was assessed as continuous variable, univariate analysis
showed that 1 unit increase in Lp(a) increases the odds of CAD
by 1.7%.and on multivariable analysis showed that the odds
remained almost similar (1.8% increase per 1 unit increase in
Lp(a), Table 3) suggesting that the risk due to Lp(a) is not
confounded by other risk factors.
The risk of CAD was also assessed using it as a categorical
variable. For this purpose Lp(a) was divided into quartiles
based on its distribution in the control populations. The Lp(a)
concentration showed a graded association with CAD. In the
first quartile of Lp(a) (<12 mg/dl), 67.7% had CAD as compared
to 68.5% in the 2nd quartile of 12e20 mg/dl, 74.5% in the 3rd
quartile of 20e40 mg/dl and 83.4% in the 4th quartile (Trend
X2 ¼ 12.65, p < 0.001, Fig. 1).
Table 4 shows odds ratio of risk for CAD for higher quartiles
of Lp(a) compared to the first quartile taken as reference both
unadjusted and multivariably adjusted for age, diabetes,
Table 3 e Univariable and multivariable regression analysis using CAD as dependent variable.
Univariable Multivariable
Variable OR (95% CI) p value AOR (95% CI) p value
Age (years) 1.013 (0.995e1.031) 0.15 1.011 (0.992e1.030) 0.275
SEX 1.323 (0.801e2.186) 0.273 e e
Diabetes mellitus 3.72 (2.163e6.396) <0.001 4.019 (2.281e7.083) <0.001
Hypertension 1.265 (0.870e1.841) 0.218 1.154 (0.762e1.747) 0.499
Smoking* 1.246 (0.854e1.818) 0.253 1.677 (1.105e2.544) 0.015
HDL cholesterol (mg/dl) 0.958 (0.936e0.981) <0.001 0.955 (0.931e0.979) <0.001
LDL cholesterol (mg/dl) 1.003 (0.999e1.007) 0.197 1.0 (0.996e1.005) 0.955
Triglycerides (mg/dl) 1.003 (1e1.006) 0.04 1.003 (1e1.006) 0.088
Lp(a) (mg/dl) 1.017 (1.009e1.025) <0.001 1.018 (1.010e1.027) <0.001
OR e odds ratio, AOR e adjusted odds ratio.
Risk factors which showed an association with CAD in univariate analysis, defined by p value 0.25 were included in analysis.
*Smoking was included as the p value was close to 0.25.
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model also, risk of CAD increased with increase in concen-
tration of Lp(a) (p value for trend, 0.0026) but the odds ratio
was statistically significant only in the highest quartile (OR 2.6
CI 1.530e4.684, p ¼ 0.001) corresponding to Lp(a) value above
40 mg/dl compared to Lp(a) <12 mg/dl. Similarly, adjusted
odds ratio for CAD achieved statistical significance only in the
highest quartile compared to Lp(a) less than 20 mg/dl (50th
percentile of our control population with odds ratio of 2.65 CI
1.622-4.330, p < 0.001, data not shown). We also analyzed the
odds ratio of subjects with Lp(a) >40 mg/dl (i.e value above
75th percentile compared to those with Lp(a) 40 mg/dl and
multivariably adjusted odds ratio of CAD was 2.308 (CI
1.465e3.636, p< 0.001). Hence in our study, subjects with Lp(a)
above the 75th percentile had statistically significant
increased risk of CAD compared to those with lower Lp(a)
levels, suggesting that there is a threshold of Lp(a) concen-
tration beyond which the risk of CAD increased significantly.5. Discussion
Lp(a), a circulatory lipoprotein was discovered in 1963 by the
Norwegian physician Kaare Berg16 and the year 2013 marks67.70% 68.50%
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Fig. 1 e Percentage of patients with CAD accordingthe 50th year of its journey as a clinically relevant lipoprotein.
Over the last 50 years, Lp(a) has evolved from an antigenic
determinant in blood type to the strongest genetically deter-
mined risk factor for coronary artery disease.17e20
Lp(a) is an LDL like particle which has apolipoprotein (a)
attached to apolipoprotein (B) molecule via a disulphide bond.
There are 34 different Lp(a) isoforms depending on the size of
the apolipoprotein(a). This has resulted in significant vari-
ability in measured Lp(a) concentration if assays used are
sensitive to variation in number of repeat domain in
apo(a).21,22Hence in 2003, an expert panel recommended use
of assay systems not sensitive to apo(a) isoforms23 and was
accepted by World Health Organization (WHO) in 2003.24 In
our study, the kit used to asses Lp(a) level was isoform
insensitive confirming to norms laid down by WHO. The rate
of secretion by liver determines the Lp(a) levels. Apolipopro-
tein(a) has a close homology with plasminogen, which makes
this molecule important not only in the process of athero-
sclerosis but also in thrombosis. While Lp(a) promotes
atherosclerosis by increasing smooth cell proliferation and
enhancing LDL-C retention in the subintima, it promotes
thrombosis by competitively inhibiting plasminogen and
upregulating expression of plasminogen activator inhibitor
(PAI).2574.50%
83.40%
20.1 - 40 mg/dl >40 mg/dl
les of Lp(a)
5 , p value < 0.001
to quartiles of Lp(a) defined from control group.
Table 4 eMultivariable logistic regression expressing OR
and 95% CIs for quartiles of Lp(a) whilst adjusting for age,
diabetes, smoking, hypertension and lipid parameters
(LDL cholesterol, HDL cholesterol and triglycerides).
Quartiles of Lp(a) (range, mg/dl)a
1 (<12) 2 (12e20) 3 (20.1e40) 4 (>40)
Cases (n) 88 74 117 171
Controls (n) 42 34 40 34
Unadjusted
OR (95% CI)
1 1.039
(0.601e1.796)
1.396
(0.835e2.334)
2.4
(1.427e4.038)
p value 0.892 0.203 <0.001
p value for trend ¼ 0.0004
Adjusted
OR (95% CI)
1 1.040
(0.583e1.855)
1.432
(0.831e2.469)
2.652
(1.520e4.629)
p value 0.894 0.196 0.001
p value for trend ¼ 0.00026
a Quartiles were defined according to Lp(a) distribution in control
population.
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bution with a tail towards the highest levels (Fig. 2). This is in
agreement with earlier studies conducted in the India.1,2,10e12
Vashisht et al26 in 1992 were the first to demonstrate the
presence of elevated Lp(a) in patients of CAD from North
India. This was however a qualitative study which had
shown that male patients aged less than 40 years, had three
times higher incidences of detectable Lp(a) in comparison to
control group. Since then, only few small studies have been
conducted from North India which have shown the associa-
tion of Lp(a) with CAD.1,2,10e13,27 The total numbers of pa-
tients enrolled in these studies were around seven hundred
only and the methods used for assays were also different
(Table 5). Hence, to draw definite conclusion about the me-
dian level of Lp(a) and its association with CAD, there was a
need to study a larger population from North India by using a
standard technique of Lp(a) estimation endorsed by WHO. In
our study we found that Lp(a) level assessed by an isoform
insensitive assay is an independent risk factor for CAD at a
concentration above 40 mg/dl corresponding to the 75thFig. 2 e Histogram showing distributionpercentile of our control population. Our findings are in
agreement with studies carried on the white population in
Europe and USA reporting that only high Lp(a) concentration
(corresponding to the top 20e25% of Lp(a) distribution) are
associated with two to three fold increased risk of CAD.8,28e30
Accordingly the European Atherosclerosis Society Consensus
Panel31 has defined Lp(a) level above the 80th percentile(-
corresponding to the 50 mg/dl) to be independently associ-
ated with increased risk of CAD. Our study is the first
adequately powered study in the North Indian population to
show that Lp(a) above the 75th percentile is an independent
risk factor for CAD, similar to that proposed by the National
Heart Lung and Blood Institute for North American Whites
based on the Framingham Heart Study.23
Hoogeveen RC et al27 had proposed a cut off value of Lp(a)
of >19 mg/dl on a study in 103 North Indian subjects (57 cases
and 46 controls) based on the fact that 25% of the cases
compared to 8% of controls in their study had Lp(a) in the
highest quartile (>19 mg/dl). However in their study, Lp(a)
proteinwas assessed by enzyme linked immunosorbant assay
and value of Lp(a)masswas obtained indirectly bymultiplying
Lp(a) protein by conversion factor of 3.3. So indirect estima-
tion of Lp(a) may have underestimated the true Lp(a) con-
centration. Gupta et al1 had used the same isoform insensitive
kit as ours to assess Lp(a) level in a small case control study (48
cases and 23 controls) in North Indian subjects of Jaipur. In
that study, Lp(a) concentration of 20e30 mg/dl failed to show
statically significant increased risk of CAD similar to our
study. However they had not evaluated the risk of CAD at
higher levels of Lp(a).
Rajasekhar et al,3 in a study from South India enrolling
151 patients have shown that Lp(a) >25 mg/dl is associ-
ated independently with around two fold risk of CAD.
Larger studies from various part of the country (Eastern,
Western and Central India) are needed to find out the
level of Lp(a) associated with increased risk CAD as this
will help in better risk stratification of subjects (with or
without CAD) and its management. In our study, the
median level of Lp(a)in the control group [20 mg/dl] is
much higher than that reported among whites (6 mg/dl),of Lp(a) levels in controls and cases.
Table 5 e Studies of Lp(a) in North Indian population.
Study No. of patients Methods of Lp(a) estimation Mean Lp(a) levels (mg/dl)
Present Study 450 Immunoturbidimetry 41.33  38.46
Ashfaq F et al (2013)13 270 Immunoturbidimetry 48.73  23.85
Geethanjali et al (2003)10 133 ELISA 41.90
Hoogeveen et al (2001)27 56 ELISA 12.65  9.4
Gupta et al (2000)1 48 Immunoturbidimetry 11.95  2.8a
Gambhir et al (2000)2 50 ELISA 35  32.4
Vashisht et al (2000)12 88 ELISA 40.90  34.05
Gupta et al (1996)11 77 Immunoturbidimetry 83.83  22.09a
a Geometric mean  standard deviation.
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abroad (16 mg/dl).33
In our study, Lp(a) level was significantly higher in patients
presenting with acute coronary syndrome as compared to
those presenting with chronic stable angina (p < 0.001). Pa-
tients presenting with acute coronary syndrome comprised
55.8% of the total cases. Dangas et al34 have shown that Lp(a) is
distributed in larger amounts in the tissues from culprit le-
sions in the patients with unstable angina compared to those
with stable angina. Stubbs et al35 have also shown that Lp(a) is
significantly higher in patients with non ST elevation
myocardial infarction. Our study also support the role of Lp(a)
in development of acute coronary syndrome justifying the
hypothesis of Lp(a) producing prothrombotic state by
competing with fibrin binding, inhibiting fibrinolysis and
promoting platelet aggregation.
Zampoulkis et al,36 studied the relationship of Lp(a) excess
with the extent and severity of atherosclerosis in CADpatients
and found that Lp(a) is related to diffuse lesions covering large
part of coronary vasculature. Budde et al,37 showed that Lp(a)
levels correlated with the length of coronary lesions as well as
the number of diseased vessels especially those with total
occlusions. Similarly in our study, highest Lp(a) levels was
observed in triple vessel disease followed by double vessel and
single vessel disease and similar findings have been reported
by Ashfaq et al13 and Gupta et al11 on studies in North Indian
population. This finding together with the finding of higher
Lp(a) values in patients with acute coronary syndrome suggest
the role of Lp(a) in pathogenesis of both atherosclerosis and
thrombosis.
Low HDL cholesterol is an independent risk factor for CAD.
In our study also, low HDL-C was found to be an independent
risk factor for CAD which is in agreement with other Indians
studies2,11,38 Most of our cases (89.5%, n ¼ 403) were estab-
lished cases of CAD andwere receiving standard doses of lipid
lowering drugs. Hence LDL-C and triglyceride levels were
similar between cases and controls. In our study, Lp(a) level
was significantly higher in patients with LDL cholesterol
>130 mg/dl compared to those with LDL <130 mg/dl (median
52.71 mg/dl vs. 30 mg/dl, p ¼ 0.02). This is due to the fact that
LDL cholesterol calculated by Friedewald equation also in-
cludes the cholesterol carried in Lp(a).
Based on our data, we feel that apart from routine lipid
profile, Lp(a) should be assessed in all patients of CAD.
Statins, the wonder drug for managing dyslipidaemia along
with fibrates and ezetimibe has unfortunately no effects on
Lp(a) level.39,40 However niacin in dose of 2 g/day has beenshown to decrease Lp(a) by 25% and increase HDL by 40%41
though it was not effective in reducing clinical end points as
reported recently.42,43 But to answer the question as to
whether reduction of Lp(a) per se reduces risk of future
adverse coronary events there is a need to develop a drug
which selectively decreases Lp(a) only without effect on
other lipid factors like LDL, HDL or TG .Selective reduction
of Lp(a) only by lipid plasmapheresis has been shown to
decrease risk of future adverse coronary events44 and clin-
ical development of specific Lp(a) lowering agents like Far-
nesoid X receptor agonists45 will allow us to know the effect
of selective Lp(a) reduction on future adverse cardiovascular
events.
We also feel that Lp(a) should be routinely assessed in all
our subjects with multiple risk factors for CAD (intermediate
to high Framingham risk score) as has been recommended by
The European Atherosclerosis Society31 and The National
Lipid Association46 to better predict the risk of developing
CAD.6. Limitation of study
We had enrolled only symptomatic patients of CAD referred
for coronary angiography and had not included the entire
spectrum of CAD patients. Hence the Lp(a) levels assessed in
our study may not be representative of all patients with CAD.
Secondly, majority of our patient were established cases of
CAD on standard doses of lipid lowering drugs, which may
have altered the association of lipids with CAD in the multi-
variable regression analysis. However none of our patients
were on niacin, which lowers Lp (a) levels.7. Conclusion
This is the largest study till date from North India showing
Lp(a) above 40 mg/dl assessed by an isoform insensitive
assay is an independent risk factor for CAD. Raised Lp(a) level
is also associated with increased risk of ACS and multivessel
CAD.Conflicts of interest
All authors have none to declare.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 2 7 2e2 7 9278Acknowledgment
We are grateful to technical staff, Department Of biochem-
istry, G B Pant Hospital, New Delhi for their assistance.r e f e r e n c e s
1. Gupta R, Kastia S, Rastogi S, et al. Lipoprotein (a) in Coronary
heart disease: a case-control study. Ind Heart J.
2000;52:407e410.
2. Gambhir JK, Kaur H, Gambhir DS, et al. Lipoprotein (a) as an
independent risk factor for Coronary artery disease in
patients below 40 years of age. Ind Heart J. 2000;52:411e415.
3. Rajasekhar D, Saibaba KSS, Rao PVLNS, et al. Lipoprotein (a):
better assessor of coronary heart disease risk in South Indian
population. Ind J Clin Biochem. 2004;19:53e59.
4. Enas EA, Chako V, Senthilkumar A, et al. Elevated lipoprotein
(a)-A genetic risk factor for premature vascular disease in
people with or without standard risk factors : a review. Dis
Mon. 2006;52:5e50.
5. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights.
Curr Opin Lipidol. 1999;10:225e236.
6. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a)
and coronary heart disease risk: a nested case-control study
of the Helsinki Heart Study participants. Atherosclerosis.
1991;89:59e67.
7. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study
of lipoprotein(a) and the risk of myocardial infarction. JAMA.
1993;270:2195e2199.
8. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al.
Genetically elevated lipoprotein(a) and increased risk of
myocardial infarction. JAMA. 2009;301:2331e2339.
9. The Emerging Risk Factors Collaboration, Erqou S, Kaptoge S,
Perry PL, et al. Lipoprotein(a) concentration and the risk of
coronary heart disease, stroke, and nonvascular mortality.
JAMA. 2009;302:412e423.
10. Geethanjali FS, Luthra K, Lingenhel A, et al. Analysis pf the
apo(a) size polymorphism in Asian Indian populations:
association with Lp(a) concentration and coronary heart
disease. Atheroscelerosis. 2003;169:121e130.
11. Gupta R, Vashisht S, Bahl VK, et al. Correlation of lipoprotein
(a) to angiographically defined coronary artery disease in
Indians. Intern J Cardiol. 1996;57:265e270.
12. Vashisht S, Gulati R, Srivastava LM, et al. Apolipoprotein (a)
polymorphism and its association with plasma lipoprotein
(a): a North Indian study. Ind Heart J. 2000;52:165e170.
13. Ashfaq F, Goel PK, Sethi R, et al. Lipoprotein (a) levels in
relation to severity of coronary artery disease in North Indian
patients. Heart Views. 2013;14:12e16.
14. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score
for unstable angina/non-ST elevation Mi: a method for
prognostication and therapeutic decision making. JAMA.
2000;284:835e842.
15. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge. Clin
Chem. 1972;18:499e502.
16. Berg K. A new serum type system in man e the Lp system.
Acta Pathol Microbiol Scand. 1963;59:369e382.
17. Li Y, Luke MM, Shiftman D, et al. Genetic variants in the
apolipoprotein (a) gene and coronary heart disease. Circ
Cardiovasc Genet. 2011;4:565e573.
18. Kronenberg F, Utermann G. Lipoprotein (a): resurrected by
genetics. J Intern Med. 2013;273:6e30.19. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al.
Apolipoprotein (a) genetic sequence variants associated with
systemic atherosclerosis and coronary atheroscelerotic
burden but not with venous thromboembolism. J Am Coll
Cardiol. 2012;60:722e729.
20. Erqou S, Thompson A, Di Angelantonio E, et al.
Apolipoprotein (a) isoforms and the risk of vascular disease:
systemic review of 40 studies involving 58,000 participants. J
Am Coll Cardiol. 2010;55:2160e2167.
21. Mclean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of
human apolipoprotein (a) is homologous to plasminogen.
Nature. 1987;330:132e137.
22. Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of
apolipoprotein (a) kringle 4 domains on immunochemical
measurements of lipoprotein (a). Clin Chem. 1995;41:246e255.
23. Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the
National Heart, Lung and Blood Institute Workshop on
Lipoprotein(a) and cardiovascular disease: recent advances
and future directions. Clin Chem. 2003;49:1785e1796.
24. Dati F, Tate JR, Marcovina SM, et al, International Federation
of Clinical Chemistry and Laboratory Medicine; IFCC Working
Group for Lipoprotein(a) Assay Standardization. First WHO/
IFCC International reference reagent for lipoprotein (a) for
immunoassay e Lp(a) SRM 2B. Clin Chem Lab Med.
2004;42:670e676.
25. Morrisett JD. The role of lipoprotein(a) in atherosclerosis. Curr
Atheroscler Rep. 2000;2:243e250.
26. Vashisht S, Wasir HS, Srivastava LM. Association between
incidence of lipoprotein positivity and coronary heart disease.
Ind Heart J. 1992;44:223e226.
27. Hoogeveen RC, Ghambir JK, Gambhir D, et al. Evaluation of
Lp(a) and other independent risk factors for CHD in Asian
Indians and their USA counterparts. J Lipid Res.
2001;42:631e638.
28. Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a) as predictor of
coronary heart disease: the PRIME Study. Atherosclerosis.
2002;163:377e384.
29. Sweetnam PM, Bolton CH, Downs LG, et al.
Apolipoproteins A-I, A-II and B, Lp(a) and the risk of
ischaemic heart disease : the Caerphilly study. Eur J Clin
Invest. 2000;30:947e956.
30. Rifal N, Ma J. Apolipoprotein(a) concentration and further risk
of angina pretoris with evidence of severe coronary
atherosclerosis in men: the Physicians Health Study. Clin
Chem. 2004;50:1364e1371.
31. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as
a cardiovascular risk factor: current status. Eur Heart J.
2010;31:2844e2853.
32. Wang W, Hu D, Lee ET, et al. Lipoprotein (a) in American
Indians is low and not independently associated with
cardiovascular disease. The Strong Heart Study. Ann
Epidemiol. 2002;12:107e114.
33. Anand SS, Enas EA, Pogue J, et al. Elevated lipoprotein(a)
levels in South Asians in North America. Metabolism.
1998;47:182e184.
34. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and
inflammation in human coronary atheroma association with
severity of clinical presentation. J Am Coll Cardiol.
1998;32:2035e2042.
35. Stubbs P, Seed M, Moseley D, et al. A prospective study of the
role of lipoprotein(a) on the pathogenesis of unstable angina.
Eur Heart J. 1997;18:603e607.
36. Zampoulkis JD, Kyriakousi AA, Poralis KA, et al. Lipoprotein(a)
is related to the extent of lesions in the coronary vasculature
and to unstable coronary syndromes. Clin Cardiol.
2000;23:895e900.
37. Budde T, Fechtrup C, Bosenberg E, et al. Plasma Lp(a) levels
correlate with number, severity, and length-extension of
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 2 7 2e2 7 9 279coronary lesions in male patients undergoing coronary
arteriography for clinically suspected coronary
atherosclerosis. Arterioscler Thromb. 1994;14:1730e1736.
38. Panwar RB, Gupta R, Gupta BK, et al. Atherothrombotic risk
factors & premature coronary heart disease in India: a case e
control study. Indian J Med Res. 2011 J;134:26e32.
39. Kostner GM, Gavish D, Leopold B, et al. HMG Co A reductase
inhibitors lower LDL cholesterol without reducing Lp(a)
levels. Circulation. 1989;80:1313e1319.
40. Berthold HK, Berthold IG. Hyperlipoproteinemia(a): clinical
significance and treatment options. Atheroscler Suppl.
2013;14:1e5.
41. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients
with low HDL cholesterol levels receiving intensive statin
therapy. N Engl J Med. 2011;365:2255e2267.
42. Albers JJ, Slee A, O’Brien KD, et al. Relationship of
apolipoprotein A-1 and B and lipoprotein(a) to cardiovascular
outcomes in the AIM-High trial. J Am Coll Cardiol.
2013;62:1575e1579.43. Haynes R, Jiang L, Hopewell JC, et al. HPS2-THRIVE
randomised placebo controlled trial in 25673 high risk
patients of ER niacin/laropiprant: trial design, prespecified
muscle and liver outcomes, and reasons for stopping study
treatment. Eur Heart J. 2013;34:1279e1291.
44. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study
on the effectiveness of lipid apheresis treatment to reduce
high lipoprotein(a) levels and prevent major adverse
coronary events. Nat Clin Pract Cardiovasc Med.
2009;6:229e239.
45. Chennamsetty I, Claude T, Kostner KM, et al. Farnesoid X
receptor hepatic human APO A gene expression. J Clin Invest.
2011;121:3724e3734.
46. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical
utility of inflammatory markers and advance lipoprotein
testing: advice from an expert panel of lipid specialists. J Clinl
Lipidol. 2011;5:338e367.
